Geron Corp
GERNHealthcare|Biotechnology|USA
$1.50
-0.07 (-4.15%)
Tangible Book
$0.36
About
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Stock Price
+8.7%(1Y)
Pipeline Summary
24 total trials11
Phase 1
9
Phase 2
2
Phase 3
1
Phase 4
Completed: 15Active: 3NOT_YET_RECRUITING: 1Withdrawn: 1Recruiting: 3APPROVED_FOR_MARKETING: 1
Active Trials (6)
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156Myelofibrosis
Phase 3Active
Enrollment: 327 participants
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT02598661Myelodysplastic Syndromes
Phase 2Phase 3Active
Enrollment: 289 participants
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
NCT05583552Myelodysplastic Syndromes
Phase 2Active
Enrollment: 46 participants
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
NCT05371964Myelofibrosis
Phase 1Recruiting
Enrollment: 36 participants
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
NCT06247787Recurrent Childhood Acute Myeloid Leukemia
Phase 1Recruiting
Enrollment: 36 participants
BioScore
5.3/10
Watchlist
Ownership
Recent Insider Trades
ROBERTSON MICHELLESELL
2026-02-189,855 shares @ $1.94
LAWLIS V BRYANBUY
2025-05-0913,300 shares @ $1.18
Samuels Scott AlanBUY
2025-02-2715,000 shares @ $1.61
SCARLETT JOHN ABUY
2025-02-2712,500 shares @ $1.77
Ziegler JamesBUY
2025-02-27100,000 shares @ $1.6
Data last updated: Jul 13, 2026, 12:48 PM